In vitro models for neuropathic pain phenotypic screening in brain therapeutics.
Pharmacol Res
; 202: 107111, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38382648
ABSTRACT
The discovery of brain therapeutics faces a significant challenge due to the low translatability of preclinical results into clinical success. To address this gap, several efforts have been made to obtain more translatable neuronal models for phenotypic screening. These models allow the selection of active compounds without predetermined knowledge of drug targets. In this review, we present an overview of various existing models within the field, examining their strengths and limitations, particularly in the context of neuropathic pain research. We illustrate the usefulness of these models through a comparative review in three crucial areas i) the development of novel phenotypic screening strategies specifically for neuropathic pain, ii) the validation of the models for both primary and secondary screening assays, and iii) the use of the models in target deconvolution processes.
Palabras clave
Early drug discovery; Felodipine (PubChem CID: 3333); Immortalized cell lines; In vitro models; In vitro pharmacology; Melatonin (PubChem CID: 896); Neuropathic pain; Nicardipine (PubChem CID: 4474); Nimodipine (PubChem CID: 4497); Nitrendipine (PubChem CID: 4507); Phenotypic screening; Pregabalin (PubChem CID: 5486971); Protriptyline (PubChem CID: 4976); Rilpivirine (PubChem CID: 6451164); Vincristine (PubChem CID: 5978); Zalcitabine (PubChem CID: 24066); α-lipoic acid (PubChem CID: 53259805)
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neuralgia
Límite:
Humans
Idioma:
En
Revista:
Pharmacol Res
Asunto de la revista:
FARMACOLOGIA
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Países Bajos